[Federal Register Volume 83, Number 175 (Monday, September 10, 2018)]
[Proposed Rules]
[Pages 45574-45578]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-19385]


 ========================================================================
 Proposed Rules
                                                 Federal Register
 ________________________________________________________________________
 
 This section of the FEDERAL REGISTER contains notices to the public of 
 the proposed issuance of rules and regulations. The purpose of these 
 notices is to give interested persons an opportunity to participate in 
 the rule making prior to the adoption of the final rules.
 
 ========================================================================
 

  Federal Register / Vol. 83, No. 175 / Monday, September 10, 2018 / 
Proposed Rules  

[[Page 45574]]


=======================================================================
-----------------------------------------------------------------------

BUREAU OF CONSUMER FINANCIAL PROTECTION

12 CFR Chapter X

[Docket No. CFPB-2018-0023]


Policy to Encourage Trial Disclosure Programs

AGENCY: Bureau of Consumer Financial Protection.

ACTION: Notice of proposed policy guidance; request for comment.

-----------------------------------------------------------------------

SUMMARY: The Bureau of Consumer Financial Protection (Bureau) invites 
the public to take this opportunity to comment on its proposal to 
create a Disclosure Sandbox through its revised Policy to Encourage 
Trial Disclosure Programs (Policy or TDP Policy), which is intended to 
carry out the Bureau's authority under Section 1032(e) of the Dodd-
Frank Wall Street Reform and Consumer Protection Act of 2010 (Dodd-
Frank Act).

DATES: Written comments are encouraged and must be received on or 
before October 10, 2018.

ADDRESSES: You may submit comments, identified by Docket No. [CFPB-
2018-0023], by any of the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov. 
Follow the instructions for submitting comments.
     Email: [email protected]. Include Docket 
No. [CFPB-2018-0023] in the subject line of the email.
     Mail/Hand Delivery/Courier: Comment Intake, Bureau of 
Consumer Financial Protection, 1700 G Street NW, Washington, DC 20552.
    Instructions: All submissions should include the agency name and 
docket number. Because paper mail in the Washington, DC area and at the 
Bureau is subject to delay, commenters are encouraged to submit 
comments electronically. In general, all comments received will be 
posted without change to http://www.regulations.gov. In addition, 
comments will be available for public inspection and copying at 1700 G 
Street NW, Washington, DC 20552, on official business days between the 
hours of 10 a.m. and 5 p.m. Eastern Time. You can make an appointment 
to inspect the documents by telephoning (202) 435-7275. All comments, 
including attachments and other supporting materials, will become part 
of the public record and subject to public disclosure. Sensitive 
personal information, such as account numbers or Social Security 
numbers, should not be included. Comments generally will not be edited 
to remove any identifying or contact information.

FOR FURTHER INFORMATION CONTACT: For additional information about the 
revised Policy, contact Paul Watkins, Assistant Director, Office of 
Innovation at [email protected] or 202-435-7000. If you 
require this document in an alternative electronic format, please 
contact [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    In subsection 1032(e) of the Dodd-Frank Act, Congress gave the 
Bureau authority to provide certain legal protections to companies to 
conduct trial disclosure programs.\1\ This authority furthers the 
Bureau's statutory purpose, stated in subsection 1021(a) of the Act, to 
ensure that all consumers have access to markets for consumer financial 
products and services and that markets for consumer financial products 
and services are fair, transparent, and competitive.\2\ Furthermore, 
this authority advances the Bureau's statutory objectives in subsection 
1021(b) of the Act to ensure consumers are provided with timely and 
understandable information to make responsible decisions about 
financial transactions; outdated, unnecessary, or unduly burdensome 
regulations are regularly identified and addressed in order to reduce 
unwarranted regulatory burdens; and markets for consumer financial 
products and services operate transparently and efficiently to 
facilitate access and innovation.\3\
---------------------------------------------------------------------------

    \1\ 12 U.S.C. 5532(e).
    \2\ 12 U.S.C. 5511(a).
    \3\ 12 U.S.C. 5511(b)(1), (b)(3), (b)(5).
---------------------------------------------------------------------------

    More specifically, under section 1032(e), the Bureau may permit 
companies to conduct trial disclosure programs, limited in time and 
scope, to improve upon existing disclosures.\4\ Such permission may 
include providing a legal safe harbor; i.e., the Bureau may deem a 
company conducting such a program to be in compliance with, or exempt 
from, a requirement of a rule or enumerated consumer law.\5\ Such trial 
disclosure programs must be subject to standards and procedures that 
are designed to encourage companies to conduct such programs.\6\ 
Similarly, although Bureau rules must provide for public disclosure of 
such programs, such public disclosure may be limited to the extent 
necessary to encourage covered persons to conduct effective trials.\7\
---------------------------------------------------------------------------

    \4\ 12 U.S.C. 5532(e)(1).
    \5\ 12 U.S.C. 5532(e)(2).
    \6\ 12 U.S.C. 5532(e)(1), (2).
    \7\ 12 U.S.C. 5532(e)(3).
---------------------------------------------------------------------------

    Pursuant to the purposes, objectives, and authority listed above, 
the Bureau proposed its Policy to Encourage Trial Disclosure Programs 
in December 2012, and finalized the Policy in September 2013. However, 
the Policy failed to effectively encourage trial disclosure programs: 
The Bureau did not permit a single such program in the nearly five 
years since the Policy was issued.

II. Summary of the Proposed Revised Policy

    In line with the above authority, the Bureau is proposing to revise 
the Policy in order to more effectively encourage companies to conduct 
trial disclosure programs. The proposed revisions have the following 
goals: (1) Reducing the application burden and review time frame; (2) 
increasing guidance regarding the testing time frame; (3) specifying 
procedures for extensions of successful trial disclosure programs; and 
(4) providing for coordination with existing or future programs offered 
by other regulators designed to facilitate innovation.
    More specifically, the Bureau is proposing to streamline the 
application process by eliminating several elements it determined were 
redundant or otherwise unnecessary. The list of factors the Bureau 
intends to consider when reviewing applications has been substantially 
reduced for similar reasons. As a result, the Bureau's proposed review 
will now focus on the quality and persuasiveness of the application, 
especially the extent to which the trial disclosures are likely to

[[Page 45575]]

be an improvement over existing disclosures, and the extent to which 
the testing program mitigates risks to consumers. Accordingly, under 
the proposed Policy, the Bureau intends to grant or deny a formal, 
complete application for a trial disclosure waiver within 60 days of 
submission. In addition, the proposed Policy reiterates that the Bureau 
may grant waivers for disclosures that improve upon existing 
requirements based upon cost-effectiveness, delivery mechanism, or 
consumer understanding.
    As under the current Policy, during the testing period, the Bureau 
proposes to deem a testing company's trial disclosure, to the extent 
that it is used in accordance with the terms and conditions permitted 
by the Bureau, to be in compliance with, or exempted from, applicable 
Federal disclosure requirements.\8\ To facilitate the Bureau's 
awareness of the effects of trial disclosures on consumers, the 
proposed Policy clarifies that the Bureau intends to require recipients 
of such a waiver to notify the Bureau of material changes in complaint 
patterns or other information that should be investigated by the Bureau 
to determine if the trial disclosures may be causing a material, 
adverse, impact on consumer understanding.
---------------------------------------------------------------------------

    \8\ 12 U.S.C. 5532(e)(2). For convenience, this statutory 
authority to deem companies in compliance with or to exempt them 
from disclosure requirements--in each case for a limited period of 
time--is hereinafter referred to as the authority to issue waivers 
for permitted programs, irrespective of whether this authority is 
effectuated through granting a waiver directly to a testing company 
under Sections A, B and C or indirectly through an agreement with 
another regulator under Section E.
---------------------------------------------------------------------------

    The proposed Policy informs potential applicants of the Bureau's 
expectation that a two-year testing period will be appropriate in most 
cases. It also adds a new section on the important subject of 
extensions of waivers for successful trial disclosure programs. The new 
section specifies the procedures for requesting such an extension and 
clarifies the Bureau's intention to grant such requests where there is 
evidence that the trial disclosures have tested successfully. To the 
extent that testers are able to show that trial disclosures succeed in 
improving upon existing requirements, the Bureau will endeavor to amend 
disclosure rules accordingly and to permit the use of validated trial 
disclosures until such amendment is effective.
    The proposed Policy also adds a new section regarding Bureau 
coordination with other regulators that offer similar programs designed 
to facilitate consumer-beneficial innovation. This new section provides 
that the Bureau intends to coordinate operation of the TDP Policy--the 
Bureau's Disclosure Sandbox--with similar programs offered by State, 
Federal, or international regulators. It provides that the Bureau is 
interested in entering into agreements with other regulators where 
testing companies could be permitted to conduct a trial program 
pursuant to the Bureau's agreement with the regulator on specified 
procedures, rather than through the application and approval process 
described in Sections A and B.
    Finally, the proposed Policy clarifies that applications may be 
submitted by a group, such as a trade association, on behalf of its 
members, and may propose a scaled or iterative approach to testing.\9\
---------------------------------------------------------------------------

    \9\ The Bureau has also made a number of technical changes to 
the Policy to accommodate the above-described substantive revisions 
and to increase clarity.
---------------------------------------------------------------------------

    The Bureau believes significant opportunities exist to enhance 
consumer protection by facilitating innovation in financial products 
and services and enabling companies to research informative, cost-
effective disclosures. The Bureau also recognizes that in-market 
testing, involving companies and consumers in real world situations, 
may offer particularly valuable information for improving disclosure 
rules and model forms.
    The Bureau invites public comment on any aspect of the revised 
Policy. The Bureau will publish a final revised Policy after 
considering comments received. The Bureau will not accept formal 
applications until the comment period has closed and the Bureau has 
adopted a final revised Policy. However, the Bureau welcomes informal 
inquires during the comment period.

III. Regulatory Requirements

    The Bureau has concluded that, if finalized, this Policy Guidance 
would constitute an agency general statement of policy and/or a rule of 
agency organization, procedure, or practice exempt from the notice and 
comment rulemaking requirements under the Administrative Procedure Act, 
pursuant to 5 U.S.C. 553(b). Notwithstanding this conclusion, the 
Bureau invites public comment on the proposed Policy. Because no notice 
of proposed rulemaking is required, the Regulatory Flexibility Act does 
not require an initial or final regulatory flexibility analysis.\10\
---------------------------------------------------------------------------

    \10\ [thinsp]5 U.S.C. 603(a), 604(a).
---------------------------------------------------------------------------

IV. Paperwork Reduction Act

    Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501 et 
seq.), Federal agencies are generally required to seek the Office of 
Management and Budget (OMB) approval for information collection 
requirements prior to implementation. According to the PRA, the Bureau 
may not conduct or sponsor, and, notwithstanding any other provision of 
law, a person is not required to respond to an information collection 
unless the information collection displays currently a valid control 
number assigned by OMB. The information requested in Section A of this 
Policy has been previously approved by OMB and assigned OMB control 
number 3170-0039. It expires on 07/31/2019. You may access 
documentation for this OMB number on www.reginfo.gov by selecting 
``Information Collection Review'' from the main menu, clicking on 
``Search,'' and then entering the OMB control number.
    The time required to complete this information collection is 
estimated to average between 2 and 10 hours per response, including the 
time for reviewing any instructions, searching existing data sources, 
gathering and maintaining the data needed, and completing and reviewing 
the collection of information. The obligation to respond to this 
collection of information is required to obtain a benefit to the extent 
that the information is to establish eligibility for a temporary 
waiver, as described in this Policy.
    The Bureau has determined that the revisions to this Policy do not 
introduce any new or substantively or materially revised collections of 
information beyond what has been previously approved by OMB. The Bureau 
has an interest in the public's opinions regarding this determination 
as well as the public's comments regarding the estimated response time, 
suggestions for improving the usefulness of the information, or 
suggestions for reducing the burden to respond to this information 
collection. Comments regarding PRA aspects of this revised Policy may 
be submitted to the Bureau as outlined above in the ADDRESSES section 
of this document.

IV. Revised Policy To Encourage Trial Disclosure Programs

    The text of the proposed Policy is as follows.
    Consumers need timely and understandable information to make the 
financial decisions that they believe are best for themselves and their 
families. Much Federal consumer protection law, therefore, rests on the 
assumption that accurate and effective disclosures will help Americans 
understand the costs,

[[Page 45576]]

benefits, and risks of consumer financial products and services.
    In Section 1032 of the Dodd-Frank Wall Street Reform and Consumer 
Protection Act (Dodd-Frank Act), Congress gave the Bureau of Consumer 
Financial Protection (Bureau) authority to prescribe rules to ensure 
that consumers receive such disclosures, and to include in such rules 
model forms to facilitate compliance.\11\ Furthermore, in subsection 
1032(e) of the Dodd-Frank Act, Congress gave the Bureau authority to 
provide certain legal protections to companies to conduct trial 
disclosure programs.\12\ This authority furthers the Bureau's statutory 
purpose, stated in subsection 1021(a) of the Act, to ensure that all 
consumers have access to markets for consumer financial products and 
services and that markets for consumer financial products and services 
are fair, transparent and competitive.\13\ Furthermore, this authority 
advances the Bureau's statutory objectives in subsection 1021(b) of the 
Act to ensure consumers are provided with timely and understandable 
information to make responsible decisions about financial transactions; 
outdated, unnecessary, or unduly burdensome regulations are regularly 
identified and addressed in order to reduce unwarranted regulatory 
burdens; and markets for consumer financial products and services 
operate transparently and efficiently to facilitate access and 
innovation.\14\
---------------------------------------------------------------------------

    \11\ 12 U.S.C. 5532(a)-(d). For purposes of the TDP Policy, 
disclosures encompass all notifications, including notifications of 
any adverse action.
    \12\ 12 U.S.C. 5532(e).
    \13\ 12 U.S.C. 5511(a).
    \14\ 12 U.S.C. 5511(b)(1), (b)(3), (b)(5).
---------------------------------------------------------------------------

    More specifically, under section 1032(e), the Bureau may permit 
companies to conduct trial disclosure programs, limited in time and 
scope, to improve upon existing disclosures.\15\ Such permission may 
include providing a legal safe harbor; i.e., the Bureau may deem a 
company conducting such a program to be in compliance with, or exempt 
from, a requirement of a rule or enumerated consumer law.\16\ Such 
trial disclosure programs must be subject to standards and procedures 
that are designed to encourage companies to conduct such programs.\17\ 
Similarly, although Bureau rules must provide for public disclosure of 
such programs, such public disclosure may be limited to the extent 
necessary to encourage covered persons to conduct effective trials.\18\
---------------------------------------------------------------------------

    \15\ 12 U.S.C. 5532(e)(1).
    \16\ 12 U.S.C. 5532(e)(2).
    \17\ 12 U.S.C. 5532(e)(1), (2).
    \18\ 12 U.S.C. 5532(e)(3).
---------------------------------------------------------------------------

    For permitted trial disclosure programs, therefore, the Bureau 
will, for a defined period, deem a participating company to be in 
compliance with, or exempt from, identified Federal disclosure 
requirements.\19\ As a result of this determination by the Bureau, no 
basis exists under those provisions for a private suit based on the 
company's use of the trial disclosure. The same is true with respect to 
other Federal and State regulators even if they have enforcement or 
supervisory authority as to the enumerated consumer laws for which the 
Bureau has rulemaking authority. There can be no predicate for an 
enforcement or supervisory action by such a regulator that is based on 
a statutory or regulatory provisions waived by the Bureau.
---------------------------------------------------------------------------

    \19\ For convenience, this statutory authority to deem companies 
in compliance with or to exempt them from disclosure requirements--
in each case for a limited period of time--is hereinafter referred 
to as the authority to issue waivers for permitted programs, 
irrespective of whether this authority is effectuated through 
granting a waiver to a testing company under Sections A, B and C or 
pursuant to an agreement with another regulator under Section E.
---------------------------------------------------------------------------

    The Bureau also encourages applicants to confer with other Federal 
and State government officials where a proposed trial disclosure 
implicates requirements administered by such authorities. Applications 
that involve the Bureau coordinating with other such officials should 
identify the other authorities applicants have contacted with respect 
to the proposal.
    The Bureau believes that there may be significant opportunities to 
enhance consumer protection by facilitating innovation in financial 
products and services through enabling responsible companies to 
research informative, cost-effective disclosures in test programs. The 
Bureau also recognizes that in-market testing, involving companies and 
consumers in real world situations, may offer particularly valuable 
information with which to improve disclosure rules and model forms.
    The Policy implements the statutory requirement to issue standards 
and procedures for trial disclosure programs and is designed to 
encourage financial services companies to innovate by proposing and 
conducting such programs, consistent with the protections for consumers 
described in the Policy.\20\
---------------------------------------------------------------------------

    \20\ 12 U.S.C. 5532(e). As specified in section C of the Policy, 
if the Bureau permits a trial disclosure program, the terms of its 
permission will specify certain legal rights granted to the 
recipient or recipients of the waiver with respect to that program. 
Those rights, however, are based on the terms of permission, and not 
on the Policy. The Policy is not intended to nor should it be 
construed to: (1) Restrict or limit in any way the Bureau's 
discretion in exercising its authorities; (2) constitute an 
interpretation of law; or (3) create or confer upon any covered 
person (including one who is the subject of Bureau supervisory, 
investigation, or enforcement activity) or consumer, any substantive 
or procedural rights or defenses that are enforceable in any manner. 
Nor should the Policy be viewed as substituting for the normal 
process of rulemaking. In the event that information learned from 
trial disclosure programs triggers or otherwise informs follow-on 
rulemaking, the Bureau would follow the standard rulemaking process, 
which affords the public the opportunity of submitting comments on a 
proposed regulation.
---------------------------------------------------------------------------

    The Policy consists of six sections:
     Section A describes information that should be included in 
an application for a trial disclosure program waiver;
     Section B lists factors the Bureau may consider in 
deciding whether to grant an application for a waiver and specifies the 
expected time frame for the Bureau's review of formal, complete 
applications;
     Section C describes the Bureau's procedures for issuing 
waivers;
     Section D describes the Bureau's procedures for issuing 
extensions of waivers;
     Section E describes how the Bureau will coordinate with 
other regulators with respect to the Policy; and
     Section F describes disclosure of information relating to 
permitted trial disclosure program.

A. Submitting Applications for Trial Disclosure Program Waivers

    Applications for a waiver should:
    1. Identify the testing company or group of companies; \21\
---------------------------------------------------------------------------

    \21\ The Bureau intends to consider applications that involve 
testing by more than one company. A trade association or other group 
may apply on behalf of its members to test a certain disclosure. If 
a disclosure is permitted for a group, each testing company must 
notify the Bureau that the company will utilize the disclosure under 
the terms permitted for the group. Either the group must commit to 
providing testing data to the Bureau for all permitted companies 
broken down by individual company or each individual company must 
commit to providing data to the Bureau.
---------------------------------------------------------------------------

    2. Describe the new disclosures or delivery mechanisms that are to 
be tested; \22\ and how these changes are expected to improve upon 
existing disclosures or delivery mechanisms

[[Page 45577]]

with respect to cost effectiveness, increased consumer understanding, 
or otherwise;
---------------------------------------------------------------------------

    \22\ An application could include the elimination of disclosure 
requirements, modifications to an existing model form or other 
disclosures, changed delivery mechanisms, or replacement of a model 
form or existing disclosure requirements with new disclosures or 
forms. Applications should include a copy of the trial disclosures 
to be tested, a description of what they would replace, and a clear 
statement of how they would be provided to consumers. When 
applications consist of revised disclosure content--as opposed to 
revisions to delivery mechanisms--that content should be in plain 
language, reflect a clear format and design, and be succinct. If an 
application is for iterative testing, it should specify the initial 
disclosure and a description of the range or type of modifications 
intended for iterative testing.
---------------------------------------------------------------------------

    3. Provide a reasonable basis for expecting and measuring these 
improvements, such as comparisons with existing costs, or consumer 
payment/response rates for the company or the relevant industry;
    4. Identify the requested duration of the test,\23\ and the size, 
location, and nature of the consumer population involved in the test, 
and explain why those parameters were selected, including whether the 
population will be scaled or modified over the duration of the test; 
\24\
---------------------------------------------------------------------------

    \23\ The Bureau expects that a two-year testing period will be 
appropriate in most cases.
    \24\ If the applicant wishes the Bureau to coordinate with other 
regulators, the applicant should identify any governmental 
authorities that have allowed or been contacted about the trial 
disclosure in question.
---------------------------------------------------------------------------

    5. Identify any risks to consumers that may be associated with the 
proposed program, describe how the program intends to mitigate such 
risks, and explain the procedures that will be used to assess for 
potential risks to consumers during the course of the test;
    6. Identify the statutory and regulatory requirements \25\ to be 
temporarily waived in connection with the trial disclosure program; 
\26\
---------------------------------------------------------------------------

    \25\ Applicants should describe the scope of the requested 
waiver with as much specificity as practicable, in part to enable 
the Bureau to respond expeditiously to the application. The Bureau 
recognizes that in some cases it may be difficult to determine 
precisely which regulatory requirements would apply, in the normal 
course, to a proposed test disclosure. In other cases, the applicant 
may lack the legal resources to make a fully precise determination. 
In such circumstances, the applicant should provide the maximum 
specification practicable under the circumstances and explain the 
limits on further specification.
    \26\ Under subsection 1032(e)(2), the Bureau has authority to 
waive a requirement of a rule or an enumerated consumer law, as that 
term is defined in the Dodd-Frank Act. 12 U.S.C. 5481(12). As used 
in subsection 1032(e)(2), the term ``rule'' includes: (i) Rules 
implementing an enumerated consumer law; and (ii) rules implementing 
the Consumer Financial Protection Act of 2010, including rules 
promulgated by the Bureau under its authority to prevent unfair, 
abusive, or deceptive acts or practices, or to enable full, accurate 
and effective disclosure.
---------------------------------------------------------------------------

    7. Contain a commitment to and schedule for sharing test result 
data with the Bureau after the conclusion of the program, as well as 
indicating any test result data to be shared during the program; and
    8. Explain how the testing company or companies will address 
disclosure requirements for the test population at the conclusion of 
the test period.
    All applications should be submitted via email to: 
[email protected]. Submitted applications may be withdrawn at 
any time. Potential applicants are encouraged to contact the Office of 
Innovation for informal preliminary discussion of a contemplated 
proposal prior to submitting a formal, complete application.\27\
---------------------------------------------------------------------------

    \27\ The email subject line should begin ``Trial Disclosure 
Program.''
---------------------------------------------------------------------------

B. Bureau Assessment of Applications for Trial Disclosure Program 
Waivers

    To decide whether to permit a proposed trial disclosure 
program,\28\ the Bureau will consider the quality and persuasiveness of 
the application, with a particular emphasis on items covered in 
subsections A.2 and A.5.
---------------------------------------------------------------------------

    \28\ The decision whether to permit a trial disclosure program 
will be within the Bureau's sole discretion. The Bureau will review 
reasonable requests to reconsider its denial of a trial disclosure 
program.
---------------------------------------------------------------------------

    The Bureau intends to grant or deny formal, complete applications 
within 60 days of submission.

C. Waiver Procedures for Permitted Trial Disclosure Programs

    When the Bureau grants a waiver, it intends to provide the company 
or companies that receive the waiver with the specific terms and 
conditions of its permission.\29\ If a company does not follow the 
terms and conditions of the waiver, or if the Bureau determines that 
the disclosure is causing a material, adverse, impact on consumer 
understanding, the Bureau may revoke the waiver in whole or in 
part.\30\ To facilitate such a determination, the Bureau intends to 
require companies to notify the Bureau of material changes in customer 
service inquiries, complaint patterns, default rates, or other 
information that should be investigated by the Bureau to determine if 
the trial disclosures may be causing a material, adverse, impact on 
consumer understanding.
---------------------------------------------------------------------------

    \29\ If the Bureau determines not to permit a proposed trial 
disclosure program, it will inform the company of its determination.
    \30\ Before issuing a revocation, the Bureau will notify the 
affected company (or companies) of the grounds for revocation, and 
permit an opportunity to respond. If the Bureau nonetheless 
determines that the company failed to follow the terms of the 
waiver, it may offer an opportunity to correct any such failure 
before revoking the waiver. If the Bureau revokes or partially 
revokes a waiver for failure to follow the waiver's terms, it will 
do so in writing and it will specify the reason or reasons for its 
action.
---------------------------------------------------------------------------

    The Bureau expects that waiver terms and conditions will be 
specified in writing in an integrated document entitled ``1032(e) Trial 
Disclosure Waiver: Terms and Conditions.'' The document will be signed 
by the Assistant Director of the Office of Innovation or other member 
of the Office of Innovation to whom the Director of the Bureau 
delegates such signature authority.
    In addition, the Bureau expects the document will:
    1. Identify the company or group of companies that are receiving a 
waiver;
    2. Specify the new disclosure(s) or delivery methods to be used by 
the company or companies under the terms of the waiver;
    3. Specify the scope of the waiver provided by the Bureau during 
the test period for the testing company or companies; \31\
---------------------------------------------------------------------------

    \31\ The waiver may be as limited as a specific provision or as 
broad as all requirements applicable to a particular disclosure, 
including specifically identified provisions.
---------------------------------------------------------------------------

    4. Specify the duration of the waiver;
    5. Describe the test population(s);
    6. State that, in the exercise of its discretion, the Bureau will 
not make supervisory findings or bring a supervisory or enforcement 
action against the company or companies under its authority to prevent 
unfair, abusive, or deceptive acts or practices predicated upon its or 
their use of the trial disclosures during the waiver period, provided 
the company engages in good faith, substantial, compliance with the 
terms of the waiver; and
    7. Specify any other conditions on the effectiveness of the waiver, 
such as the terms of testing, data sharing, certification of compliance 
with the terms of the waiver, and/or public disclosure.\32\
---------------------------------------------------------------------------

    \32\ The procedures specified in section C may be modified 
pursuant to coordination efforts with other regulators. See section 
E below.
---------------------------------------------------------------------------

D. Procedures for Extension of Trial Disclosure Program Waivers

    Waiver recipients may reapply by resubmitting the entirety of the 
information required under Section A. As an alternative, waiver 
recipients may request an extension for a specified period of time 
based upon the quality and persuasiveness of the test result data 
required to be provided to the Bureau under subsection A.7. The Bureau 
expects to place particular weight upon whether the data supports the 
objectives identified in the application under subsections A.2 and A.5 
to improve upon existing disclosures, without causing a material, 
adverse, impact on consumer understanding. Such requests for an 
extension should include the duration of the requested extension and 
should be submitted no later than 150-days prior to the expiration of 
the waiver.\33\
---------------------------------------------------------------------------

    \33\ Assuming the two-year testing period the Bureau expects to 
be appropriate in most cases, the Bureau believes the testing 
company(s) would have sufficient time to gather evidence supportive 
of an extension request.

---------------------------------------------------------------------------

[[Page 45578]]

    Upon the presentation of persuasive test result data, the Bureau 
anticipates permitting such extension requests for a period at least as 
long as the period of the original waiver. The Bureau anticipates 
permitting longer extensions where the Bureau is considering amending 
disclosure requirements in a manner consistent with the trial 
disclosures in question.\34\ During the time period pending a rule 
amendment, the Bureau intends to consider means of making the improved 
disclosure available to other covered entities.
---------------------------------------------------------------------------

    \34\ Rule amendments that follow successful trial disclosure 
tests could continue to permit all existing disclosure practices--
allowing an additional and alternative method of compliance, rather 
than replacing existing requirements with new ones. If the period of 
an extension were tied to the Bureau's consideration of amending 
relevant disclosure requirements and the Bureau announced it was 
discontinuing its plans to amend the disclosure rules in question, 
such a waiver would be revised to be for a period of a fixed length 
or revoked after reasonable notice to the testing company(s).
---------------------------------------------------------------------------

E. Regulatory Coordination

    Subsection 1015 of the Dodd-Frank Act instructs the Bureau to 
coordinate with . . . Federal agencies and State regulators, as 
appropriate, to promote consistent regulatory treatment of consumer 
financial and investment products and services.\35\ Similarly, 
subsection 1042(c) of the Act instructs the Bureau to provide guidance 
in order to further coordinate actions with the State attorneys general 
and other regulators.\36\ The Bureau's direction to coordinate includes 
coordinating circumstances where States have chosen to limit their 
enforcement or other regulatory authority. One method of limiting such 
authority is through a State sandbox, or group of State sandboxes, or 
other limited scope State authorization program (``State 
sandbox'').\37\ The Bureau is interested in entering into agreements 
with State authorities designed to improve upon existing disclosure 
requirements \38\ by allowing covered persons to test disclosures 
within the state sandbox. Specifically, the Bureau expects that, in 
specified circumstances, such entities could receive permission to 
conduct a trial disclosure program pursuant to the Bureau's agreement 
with the State authority, rather than through the process described in 
Sections A, B, and C. The Bureau is interested in negotiating 
agreements that include the following features. First, the State 
sandbox must contain safeguards that protect consumers from deception. 
Second, the State sandbox must be limited in time or scope. Third, the 
State sandbox entity must agree to provide the Bureau with data to 
assist the Bureau in assessing whether the disclosure (or disclosures) 
used within the scope of the state sandbox improves upon existing 
disclosures based upon cost effectiveness, consumer understanding, or 
otherwise. Alternatively, the State authority may agree to periodically 
provide the Bureau with such data regarding the disclosures used by 
participants in the State sandbox.
---------------------------------------------------------------------------

    \35\ 12 U.S.C. 5495.
    \36\ 12 U.S.C. 5552(c).
    \37\ The concept of a regulatory sandbox is relatively new and 
does not have a precise, generally accepted definition. The term is 
used in this Policy to refer to a regulatory structure where a 
participant obtains limited or temporary access to a market in 
exchange for reduced regulatory barriers to entry or reduced 
regulatory uncertainty.
    \38\ See note 26.
---------------------------------------------------------------------------

    Under this Section, a State sandbox entity's authorization under 
the TDP Policy will be limited to the parameters of the State sandbox. 
If the entity seeks wider authorization under the TDP Policy, it must 
submit an application following the standard permission process 
detailed in Sections A, B, and C. Successful results from disclosures 
used within a State or other jurisdiction will be highly persuasive in 
supporting such an application under the TDP Policy.
    Furthermore, the Bureau wishes to coordinate with other regulators. 
To this end, the Bureau intends to enter into agreements whenever 
practicable to coordinate permission to conduct trial programs with 
similar programs operated by State, Federal, or international 
regulators.

F. Bureau Disclosure of Information Regarding Trial Disclosure Programs

    The Bureau intends to publish notice on its website of any trial 
disclosure program permitted under Section C or D.\39\ The notice will: 
(i) Identify the company or companies conducting the trial disclosure 
program; (ii) summarize the new disclosures to be used and the duration 
of their intended use; and (iii) state that the waiver applies only to 
the testing company or companies in accordance with the permitted terms 
of use.
---------------------------------------------------------------------------

    \39\ The Bureau will at minimum publish the names of companies 
conducting trial disclosure programs pursuant to Section E, but 
reserves the discretion to negotiate any additional disclosure terms 
with the corresponding regulator.
---------------------------------------------------------------------------

    Public disclosure of any other information regarding trial 
disclosure programs is governed by the Bureau's Rule on Disclosure of 
Records and Information.\40\ For example, the rule requires the Bureau 
to make available records requested by the public unless they are 
subject to a FOIA exemption or exclusion. To the extent the Bureau 
wishes to disclose information regarding trial disclosure programs, the 
terms of such disclosure will be included in the 1032(e) Trial 
Disclosure Waiver: Terms and Conditions document. Consistent with 
applicable law and its own rules, the Bureau will not seek to disclose 
any test data that would conflict with consumers' privacy interests.
---------------------------------------------------------------------------

    \40\ See 12 CFR 1070 et seq.

    Dated: August 30, 2018.
Mick Mulvaney,
Acting Director, Bureau of Consumer Financial Protection.
[FR Doc. 2018-19385 Filed 9-7-18; 8:45 am]
 BILLING CODE P